Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
European Urology
|
December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)
J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Actas Urologicas Espanolas
|
March 17, 2025
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients
M Hassi Roman, K Mate, P de Pablos-RodrIguez, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
European Urology
|
December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)
J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Actas Urologicas Espanolas
|
March 17, 2025
Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients
M Hassi Roman, K Mate, P de Pablos-RodrIguez, et al.
Page
of 5